BR112017017930A2 - o-oligossacaril-transferases de acinetobacter e usos das mesmas - Google Patents

o-oligossacaril-transferases de acinetobacter e usos das mesmas

Info

Publication number
BR112017017930A2
BR112017017930A2 BR112017017930A BR112017017930A BR112017017930A2 BR 112017017930 A2 BR112017017930 A2 BR 112017017930A2 BR 112017017930 A BR112017017930 A BR 112017017930A BR 112017017930 A BR112017017930 A BR 112017017930A BR 112017017930 A2 BR112017017930 A2 BR 112017017930A2
Authority
BR
Brazil
Prior art keywords
acinetobacter
otase
vaccines
glycoprotein
oligosaccharyl transferases
Prior art date
Application number
BR112017017930A
Other languages
English (en)
Inventor
Feldman Mario
Adel Nasr Mohamed
Original Assignee
Vaxnewmo Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxnewmo Llc filed Critical Vaxnewmo Llc
Publication of BR112017017930A2 publication Critical patent/BR112017017930A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a métodos e usos da o-oligossacaril-transferase (o-otases) para a geração de vacinas. em particular, o presente pedido apresenta um método de síntese de uma glicoproteína que compreende a glicosilação da proteína similar à pilina comp usando uma pg1lcomp o-otase. são também apresentados usos de glicoproteínas sintetizadas por comp glicosilante utilizando pg1lcomp o-otase, particularmente para a preparação de vacinas e similares, inclusive uma vacina para streptococcus.
BR112017017930A 2015-02-26 2016-02-26 o-oligossacaril-transferases de acinetobacter e usos das mesmas BR112017017930A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562121439P 2015-02-26 2015-02-26
PCT/CA2016/050208 WO2016134485A1 (en) 2015-02-26 2016-02-26 Acinetobacter o-oligosaccharyltransferases and uses thereof

Publications (1)

Publication Number Publication Date
BR112017017930A2 true BR112017017930A2 (pt) 2018-04-10

Family

ID=56787925

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017017930A BR112017017930A2 (pt) 2015-02-26 2016-02-26 o-oligossacaril-transferases de acinetobacter e usos das mesmas

Country Status (7)

Country Link
US (3) US10265391B2 (pt)
EP (1) EP3262077A4 (pt)
JP (1) JP6764872B2 (pt)
AU (1) AU2016224006B8 (pt)
BR (1) BR112017017930A2 (pt)
CA (1) CA2977561C (pt)
WO (1) WO2016134485A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016224006B8 (en) 2015-02-26 2020-03-19 Vaxnewmo Llc Acinetobacter O-oligosaccharyltransferases and uses thereof
EP3359188A1 (en) * 2015-10-07 2018-08-15 Boehringer Ingelheim Vetmedica, Inc. Streptococcus suis polysaccharide-protein conjugate composition
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP2021528059A (ja) * 2018-06-16 2021-10-21 ヴァックスニューモ エルエルシーＶａｘｎｅｗｍｏ Ｌｌｃ グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用
WO2020131236A1 (en) * 2018-12-21 2020-06-25 Vaxnewmo Llc O-linked glycosylation recognition motifs
WO2021217037A2 (en) * 2020-04-23 2021-10-28 Cornell University Bacterial system for producing human o-glycoproteins
WO2024030212A1 (en) * 2022-06-30 2024-02-08 Mechanobiologics, Inc. Reversal of cellular senescence by treatment with low frequency ultrasound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1059354A2 (en) * 1999-06-10 2000-12-13 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
ES2652416T3 (es) * 2006-12-13 2018-02-02 The Governors Of The University Of Alberta Métodos y sistemas para la O-glicosilación de proteínas
US20130196410A1 (en) 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
WO2013067523A1 (en) 2011-11-04 2013-05-10 Cornell University A prokaryote-based cell-free system for the synthesis of glycoproteins
WO2014057109A1 (en) * 2012-10-12 2014-04-17 Glycovaxyn Ag Methods of host cell modification
CA2889767C (en) * 2012-11-07 2021-09-21 Glycovaxyn Ag Production of recombinant vaccine in e. coli by enzymatic conjugation
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
EP3193918A4 (en) 2014-09-18 2018-06-20 University of Maryland, Baltimore Broad spectrum conjugate vaccine to prevent klebsiella pneumoniae and pseudomonas aeruginosa infections
WO2016107818A1 (en) 2014-12-30 2016-07-07 Glycovaxyn Ag Compositions and methods for protein glycosylation
AU2016224006B8 (en) 2015-02-26 2020-03-19 Vaxnewmo Llc Acinetobacter O-oligosaccharyltransferases and uses thereof
JP2021528059A (ja) 2018-06-16 2021-10-21 ヴァックスニューモ エルエルシーＶａｘｎｅｗｍｏ Ｌｌｃ グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用
WO2020131236A1 (en) 2018-12-21 2020-06-25 Vaxnewmo Llc O-linked glycosylation recognition motifs

Also Published As

Publication number Publication date
US20190343945A1 (en) 2019-11-14
JP2018507693A (ja) 2018-03-22
JP6764872B2 (ja) 2020-10-07
AU2016224006A1 (en) 2017-09-28
WO2016134485A1 (en) 2016-09-01
CA2977561C (en) 2022-09-06
EP3262077A4 (en) 2018-11-14
US11497804B2 (en) 2022-11-15
US20210220460A1 (en) 2021-07-22
US20180050101A1 (en) 2018-02-22
AU2016224006B8 (en) 2020-03-19
AU2016224006B2 (en) 2020-02-27
US10265391B2 (en) 2019-04-23
CA2977561A1 (en) 2016-09-01
US10869918B2 (en) 2020-12-22
EP3262077A1 (en) 2018-01-03

Similar Documents

Publication Publication Date Title
BR112017017930A2 (pt) o-oligossacaril-transferases de acinetobacter e usos das mesmas
BR112018003486A2 (pt) ?molécula, rna, métodos para obter rna, métodos para obter um peptídeo e usos do rna?
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
WO2018089851A3 (en) Influenza vaccine
ZA201802657B (en) Crystal forms of beta-nicotinamide mononucleotide
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
BR112018015485A2 (pt) imunoglobulina fabs-in-tandem e usos da mesma
BR112018071983A2 (pt) composições de limpeza e métodos para limpeza do rosto e para remover maquiagem da pele
BR112017019409A2 (pt) forma cristalina de ribosídeo de nicotinamida
BR112019001451A2 (pt) composição cosmética que compreende materiais de silicone curados
BR112017014031A2 (pt) n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado.
MX2018001213A (es) Nuevos metodos para inducir una respuesta inmunitaria.
CL2018001192A1 (es) Análogos de saponina triterpeno
BR112017002761A2 (pt) composições anti-metanogênicas e usos das mesmas
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
BR112015030229A8 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
MX2017010908A (es) Vacuna bivalente contra el virus de gripe porcina.
CL2019003064A1 (es) Análogos de triterperno saponina.
BR112017019358A2 (pt) combinações e formulações de dose fixa compreendendo etc1002 e ezetimiba e métodos de tratamento ou redução do risco de doença cardiovascular
BR112019011812A2 (pt) composições nutricionais contendo butirato e usos das mesmas
BR112015000585A8 (pt) método para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante, vacina, kit de vacinação e usos do vetor e da cepa mutante
ZA202204981B (en) Synthetic chimeric poxviruses
BR112017028212A2 (pt) vacinação concomitante contra dengue e febre amarela
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
BR112017013574A2 (pt) conjugados de aminoácido e peptídeo e usos dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024013855-7 PROTOCOLO 870240056943 EM 05/07/2024 10:15.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/02/2016, OBSERVADAS AS CONDICOES LEGAIS